NASDAQ:RSLS - Reshape Lifesciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.4110 0.00 (0.00 %)
(As of 12/18/2018 01:48 PM ET)
Previous Close$0.4111
Today's Range$0.4050 - $0.59
52-Week Range$0.40 - $3,759.00
Volume2.22 million shs
Average Volume2.05 million shs
Market Capitalization$490,000.00
P/E Ratio0.00
Dividend YieldN/A
Beta2.02
ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Its product portfolio also comprises ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

Receive RSLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:RSLS
Previous Symbol
CUSIP29365M20
Phone949-429-6680

Debt

Debt-to-Equity RatioN/A
Current Ratio0.30
Quick Ratio0.18

Price-To-Earnings

Trailing P/E Ratio0.00
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.29 million
Price / Sales0.30
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5,382.42 per share
Price / Book0.00

Profitability

EPS (Most Recent Fiscal Year)($6,714.95)
Net Income$-33,810,000.00
Net Margins-2,297.23%
Return on Equity-70.35%
Return on Assets-57.75%

Miscellaneous

Employees83
Outstanding Shares950,000
Market Cap$490,000.00
OptionableNot Optionable

Reshape Lifesciences (NASDAQ:RSLS) Frequently Asked Questions

What is Reshape Lifesciences' stock symbol?

Reshape Lifesciences trades on the NASDAQ under the ticker symbol "RSLS."

When did Reshape Lifesciences' stock split? How did Reshape Lifesciences' stock split work?

Reshape Lifesciences shares reverse split on Thursday, November 8th 2018. The 1-140 reverse split was announced on Wednesday, November 7th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 7th 2018. An investor that had 100 shares of Reshape Lifesciences stock prior to the reverse split would have 1 shares after the split.

How were Reshape Lifesciences' earnings last quarter?

Reshape Lifesciences Inc (NASDAQ:RSLS) announced its quarterly earnings data on Wednesday, November, 14th. The medical device company reported ($27.46) EPS for the quarter. The medical device company had revenue of $0.35 million for the quarter. Reshape Lifesciences had a negative net margin of 2,297.23% and a negative return on equity of 70.35%. View Reshape Lifesciences' Earnings History.

When is Reshape Lifesciences' next earnings date?

Reshape Lifesciences is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Reshape Lifesciences.

What is the consensus analysts' recommendation for Reshape Lifesciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reshape Lifesciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Reshape Lifesciences.

Has Reshape Lifesciences been receiving favorable news coverage?

Headlines about RSLS stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Reshape Lifesciences earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the near future.

Who are some of Reshape Lifesciences' key competitors?

Who are Reshape Lifesciences' key executives?

Reshape Lifesciences' management team includes the folowing people:
  • Mr. Dan W. Gladney, Chairman, Pres & CEO (Age 65)
  • Mr. Scott P. Youngstrom, CFO, Sr. VP of Fin. & Sec. (Age 58)
  • Mr. Naqeeb A. Ansari, VP of Worldwide Sales (Age 57)
  • Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)
  • Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 57)

Who are Reshape Lifesciences' major shareholders?

Reshape Lifesciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3,812.88%). View Institutional Ownership Trends for Reshape Lifesciences.

Which major investors are buying Reshape Lifesciences stock?

RSLS stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Reshape Lifesciences.

How do I buy shares of Reshape Lifesciences?

Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Reshape Lifesciences' stock price today?

One share of RSLS stock can currently be purchased for approximately $0.4325.

How big of a company is Reshape Lifesciences?

Reshape Lifesciences has a market capitalization of $490,000.00 and generates $1.29 million in revenue each year. The medical device company earns $-33,810,000.00 in net income (profit) each year or ($6,714.95) on an earnings per share basis. Reshape Lifesciences employs 83 workers across the globe.

What is Reshape Lifesciences' official website?

The official website for Reshape Lifesciences is http://www.enteromedics.com.

How can I contact Reshape Lifesciences?

Reshape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected]


MarketBeat Community Rating for Reshape Lifesciences (NASDAQ RSLS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  587
MarketBeat's community ratings are surveys of what our community members think about Reshape Lifesciences and other stocks. Vote "Outperform" if you believe RSLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel